CTA Community Poll: How Does Your Work Life Balance Compare to Your Peers?
Over a third of our respondents indicated that their job in oncology allowed them sufficient work/life balance. Surprisingly, only 6% of respondents felt they never experienced a sufficient balance between their home life and work life because of their oncology-related profession.
In this age when technology allows us to be “connected” at almost any time, in any place, we were curious about how many of you actually completely disconnected while you were away from work. About 40% of the CTA poll respondents said that they only occasionally check and respond to email while on vacation.
What does a vacation mean to you these days? Does it just mean time off to recharge, or is it an opportunity to get personal tasks accomplished? One third of CTA poll respondents use their time off to complete tasks they can't get done because of work.
Much has been discussed about “burnout” in the oncology community because of the demands of the job and the emotional and physical stress that can result. Over 38% of poll respondents indicated that their own health and happiness are affected by their work schedule.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML